Genentech beefs up its PD-L1 combo pipeline, signing the ‘don’t eat me’ specialists at Forty Seven

After expanding its partnership with Syndax $SNDX earlier this week on their lead drug, Genentech has beefed up their pipeline of PD-L1 combos with a fresh pact with Stanford spinout Forty Seven.

• Source: Endpts;
• 373
• January 15, 2018